Obesity and osteoarthritis, more than just wear and tear: Pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis

Rheumatology (United Kingdom)

Volumn 54, Issue 4, 2014, Pages 588-600

  Thijssen, Eva ^a   Van Caam, Arjan ^a   Van Der Kraan, Peter M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adipokines; Bone; Cartilage; Cytokines; Dyslipidaemia; Joint loading; Low grade inflammation; Obesity; Osteoarthritis; Synovium

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INTERLEUKIN 6; LEPTIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADIPOSE TISSUE; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE MATRIX; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; MEDICAL HISTORY; NONHUMAN; OBESITY; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC DISEASE;

EID: 84926509511     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu464     Document Type: Review

References (146)

1. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006;20:3-25.
2. Abramson SB, Attur M. Developments in the scientific understanding of osteoarthritis. Arthritis Res Ther 2009;11:227.
3. Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthr Cartil 2005;13:361-7.
4. Rollin R, Marco F, Jover JA et al. Early lymphocyte activation in the synovial microenvironment in patients with osteoarthritis: comparison with rheumatoid arthritis patients and healthy controls. Rheumatol Int 2008;28:757-64.
5. Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. Am J Epidemiol 1988;179-89.
6. Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med 1988;109:18-24.
7. Sturmer T, Gunther KP, Brenner H. Obesity, overweight and patterns of osteoarthritis: the Ulm Osteoarthritis Study. J Clin Epidemiol 2000;53:307-13.
8. Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord 2008;9:132.
9. Radin EL, Paul IL, Rose RM. Role of mechanical factors in pathogenesis of primary osteoarthritis. Lancet 1972;1:519-22.
10. Carman WJ, Sowers M, Hawthorne VM, Weissfeld LA. Obesity as a risk factor for osteoarthritis of the hand and wrist: a prospective study. Am J Epidemiol 1994;139:119-29.
11. Cicuttini FM, Baker JR, Spector TD. The association of obesity with osteoarthritis of the hand and knee in women:a twin study. J Rheumatol 1996;23:1221-6.
12. Dahaghin S, Bierma-Zeinstra SM, Koes BW, Hazes JM, Pols HA. Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study. Ann Rheum Dis 2007;66:916-20.
13. Oliveria SA, Felson DT, Cirillo PA, Reed JI, Walker AM. Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology 1999;10:161-6.
14. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
15. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity:mechanisms and potential targets. Nutrients 2013;5:1218-40.
16. Ramage L, Nuki G, Salter DM. Signalling cascades in mechanotransduction: cell-matrix interactions and mechanical loading. Scand J Med Sci Sports 2009;19:457-69.
17. Widmyer MR, Utturkar GM, Leddy HA et al. High body mass index is associated with increased diurnal strains in the articular cartilage of the knee. Arthritis Rheum 2013;65:2615-22.
18. Harding GT, Hubley-Kozey CL, Dunbar MJ, Stanish WD, Astephen Wilson JL. Body mass index affects knee joint mechanics during gait differently with and without moderate knee osteoarthritis. Osteoarthr Cartil 2012;20:1234-42.
19. Fujisawa T, Hattori T, Takahashi K et al. Cyclic mechanical stress induces extracellular matrix degradation in cultured chondrocytes via gene expression of matrix metalloproteinases and interleukin-1. J Biochem 1999;125:966-75.
20. Honda K, Ohno S, Tanimoto K et al. The effects of high magnitude cyclic tensile load on cartilage matrix metabolism in cultured chondrocytes. Eur J Cell Biol 2000;79:601-9.
21. Lin PM, Chen CT, Torzilli PA. Increased stromelysin-1 (MMP-3), proteoglycan degradation (3B3- and 7D4) and collagen damage in cyclically load-injured articular cartilage. Osteoarthr Cartil 2004;12:485-96.
22. Fermor B, Weinberg JB, Pisetsky DS et al. Induction of cyclooxygenase-2 by mechanical stress through a nitric oxide-regulated pathway. Osteoarthr Cartil 2002;10:792-8.
23. Ko FC, Dragomir C, Plumb DA et al. In vivo cyclic compression causes cartilage degeneration and subchondral bone changes in mouse tibiae. Arthritis Rheum 2013;65:1569-78.
24. Roemhildt ML, Beynnon BD, Gauthier AE et al. Chronic in vivo load alteration induces degenerative changes in the rat tibiofemoral joint. Osteoarthr Cartil 2013;21:346-57.
25. Huebner JL, Hanes MA, Beekman B, TeKoppele JM, Kraus VB. A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis. Osteoarthr Cartil 2002;10:758-67.
26. Sanchez C, Deberg MA, Bellahcene A et al. Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone. Arthritis Rheum 2008;58:442-55.
27. Sanchez C, Pesesse L, Gabay O et al. Regulation of subchondral bone osteoblast metabolism by cyclic compression. Arthritis Rheum 2012;64:1193-203.
28. Wang H, Peng DQ. New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis 2011;10:176.
29. Kwiterovich PO Jr. The metabolic pathways of highdensity lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000;86:5-10L.
30. Wu Z, Wagner MA, Zheng L et al. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol 2007;14:861-8.
31. Mutlu-Turkoglu U, Oztezcan S, Telci A et al. An increase in lipoprotein oxidation and endogenous lipid peroxides in serum of obese women. Clin Exp Med 2003;2:171-4.
32. Sturmer T, Sun Y, Sauerland S et al. Serum cholesterol and osteoarthritis. The baseline examination of the Ulm Osteoarthritis Study. J Rheumatol 1998;25:1827-32.
33. Davies-Tuck ML, Hanna F, Davis SR et al. Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women - a prospective cohort study. Arthritis Res Ther 2009;11:R181.
34. Triantaphyllidou IE, Kalyvioti E, Karavia E et al. Perturbations in the HDL metabolic pathway predispose to the development of osteoarthritis in mice following longterm exposure to western-type diet. Osteoarthr Cartil 2013;21:322-30.
35. Garnero P, Peterfy C, Zaim S, Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005;52:2822-9.
36. Hunter DJ, Zhang Y, Niu J et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum 2006;54:1529-35.
37. Tanamas SK, Wluka AE, Pelletier JP et al. Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint replacement: a longitudinal study. Rheumatology 2010;49:2413-9.
38. Felson DT, McLaughlin S, Goggins J et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003;139:330-6.
39. Lippiello L, Walsh T, Fienhold M. The association of lipid abnormalities with tissue pathology in human osteoarthritic articular cartilage. Metabolism 1991;40:571-6.
40. Tsezou A, Iliopoulos D, Malizos KN, Simopoulou T. Impaired expression of genes regulating cholesterol efflux in human osteoarthritic chondrocytes. J Orthop Res 2010;28:1033-9.
41. Soran N, Altindag O, Cakir H et al. Assessment of paraoxonase activities in patients with knee osteoarthritis. Redox Rep 2008;13:194-8.
42. Simopoulou T, Malizos KN, Tsezou A. Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human articular chondrocytes. Clin Exp Rheumatol 2007;25:605-12.
43. Sawamura T, Kume N, Aoyama T et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-7.
44. Kanata S, Akagi M, Nishimura S et al. Oxidized LDL binding to LOX-1 upregulates VEGF expression in cultured bovine chondrocytes through activation of PPAR-gamma. Biochem Biophys Res Commun 2006;348:1003-10.
45. Pufe T, Harde V, Petersen W et al. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. J Pathol 2004;202:367-74.
46. Kakinuma T, Yasuda T, Nakagawa T et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates matrix metalloproteinase 3 synthesis enhanced by oxidized low-density lipoprotein in rheumatoid arthritis cartilage. Arthritis Rheum 2004;50:3495-503.
47. Akagi M, Kanata S, Mori S et al. Possible involvement of the oxidized low-density lipoprotein/lectin-like oxidized low-density lipoprotein receptor-1 system in pathogenesis and progression of human osteoarthritis. Osteoarthr Cartil 2007;15:281-90.
48. Ishikawa M, Ito H, Akiyoshi M et al. Lectin-like oxidized low-density lipoprotein receptor 1 signal is a potent biomarker and therapeutic target for human rheumatoid arthritis. Arthritis Rheum 2012;64:1024-34.
49. Mook S, Halkes CC, Bilecen S, Cabezas MC. In vivo regulation of plasma free fatty acids in insulin resistance. Metabolism 2004;53:1197-201.
50. van Oostrom AJ, van Dijk H, Verseyden C et al. Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 3. Am J Clin Nutr 2004;79:510-5.
51. Nguyen MT, Favelyukis S, Nguyen AK et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007;282:35279-92.
52. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
53. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175-84.
54. Fujisaka S, Usui I, Ikutani M et al. Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages in an HIF-1alpha-dependent and HIF-1alpha-independent manner in obese mice. Diabetologia 2013;56:1403-12.
55. Han JM, Levings MK. Immune regulation in obesityassociated adipose inflammation. J Immunol 2013;191:527-32.
56. Distel E, Cadoudal T, Durant S et al. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum 2009;60:3374-7.
57. Ushiyama T, Chano T, Inoue K, Matsusue Y. Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann Rheum Dis 2003;62:108-12.
58. Clockaerts S, Bastiaansen-Jenniskens YM, Runhaar J et al. The infrapatellar fat pad should be considered as an active osteoarthritic joint tissue: a narrative review. Osteoarthr Cartil 2010;18:876-82.
59. Clockaerts S, Bastiaansen-Jenniskens YM, Feijt C et al. Cytokine production by infrapatellar fat pad can be stimulated by interleukin 1beta and inhibited by peroxisome proliferator activated receptor alpha agonist. Ann Rheum Dis 2012;71:1012-8.
60. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006;74:443-77.
61. Schlich R, Willems M, Greulich S et al. VEGF in the crosstalk between human adipocytes and smooth muscle cells: depot-specific release from visceral and perivascular adipose tissue. Mediators Inflamm 2013;2013:982458.
62. Miyazawa-Hoshimoto S, Takahashi K, Bujo H et al. Roles of degree of fat deposition and its localization on VEGF expression in adipocytes. Am J Physiol Endocrinol Metab 2005;288:E1128-36.
63. Ziccardi P, Nappo F, Giugliano G et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105:804-9.
64. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 2003;46:1483-8.
65. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
66. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51.
67. Martel-Pelletier JLD, Pelletier JP. Etiopathogenesis of osteoarthritis. In: Koopman W, Moreland LW, eds. Arthritis and allied conditions: a textbook of rheumatology. 15th edn. Baltimore, USA: Lippincott Williams & Wilkins, 2005:2199-226.
68. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-9.
69. Seguin CA, Bernier SM. TNFalpha suppresses link protein and type II collagen expression in chondrocytes: role of MEK1/2 and NF-kappaB signaling pathways. J Cell Physiol 2003;197:356-69.
70. Watanabe H, Yamada Y. Mice lacking link protein develop dwarfism and craniofacial abnormalities. Nat Genet 1999;21:225-9.
71. Lefebvre V, Peeters-Joris C, Vaes G. Modulation by interleukin 1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta 1990;1052:366-78.
72. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest 1996;97:2011-9.
73. Guerne PA, Carson DA, Lotz M. IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol 1990;144:499-505.
74. Lotz M, Terkeltaub R, Villiger PM. Cartilage and joint inflammation. Regulation of IL-8 expression by human articular chondrocytes. J Immunol 1992;148:466-73.
75. Villiger PM, Terkeltaub R, Lotz M. Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid. J Clin Invest 1992;90:488-96.
76. Alaaeddine N, Olee T, Hashimoto S, Creighton-Achermann L, Lotz M. Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum 2001;44:1633-43.
77. Stannus O, Jones G, Cicuttini F et al. Circulating levels of IL-6 and TNF-alpha are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthr Cartil 2010;18:1441-7.
78. Grunke M, Schulze-Koops H. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis 2006;65:555-6.
79. Magnano MD, Chakravarty EF, Broudy C et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007;34:1323-7.
80. Kaneko S, Satoh T, Chiba J et al. Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 2000;6:71-9.
81. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a downregulation of SOX9 expression. J Biol Chem 2003;278:2903-12.
82. Poree B, Kypriotou M, Chadjichristos C et al. Interleukin-6 (IL-6) and/or soluble IL-6 receptor down-regulation of human type II collagen gene expression in articular chondrocytes requires a decrease of Sp1.Sp3 ratio and of the binding activity of both factors to the COL2A1 promoter. J Biol Chem 2008;283:4850-65.
83. Flannery CR, Little CB, Hughes CE et al. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 2000;19:549-53.
84. Rowan AD, Koshy PJ, Shingleton WD et al. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 2001;44:1620-32.
85. Ryu JH, Yang S, Shin Y et al. Interleukin-6 plays an essential role in hypoxia-inducible factor 2alpha-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum 2011;63:2732-43.
86. Pelletier JP, McCollum R, Cloutier JM, Martel-Pelletier J. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J Rheumatol Suppl 1995;43:109-14.
87. Smolen JS, Schoels MM, Nishimoto N et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72:482-92.
88. Hoff P, Buttgereit F, Burmester GR et al. Osteoarthritis synovial fluid activates pro-inflammatory cytokines in primary human chondrocytes. Int Orthop 2013;37:145-51.
89. Haywood L, McWilliams DF, Pearson CI et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003;48:2173-7.
90. Lambert C, Mathy-Hartert M, Dubuc JE et al. Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther 2012;14:R58.
91. Murata M, Yudoh K, Masuko K. The potential role of vascular endothelial growth factor (VEGF) in cartilage:how the angiogenic factor could be involved in the pathogenesis of osteoarthritis? Osteoarthr Cartil 2008; 16:279-86.
92. Iwata M, Ochi H, Hara Y et al. Initial responses of articular tissues in a murine high-fat diet-induced osteoarthritis model: pivotal role of the IPFP as a cytokine fountain. PloS One 2013;8:e60706.
93. Presle N, Pottie P, Dumond H et al. Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthr Cartil 2006;14:690-5.
94. Dahlman I, Elsen M, Tennagels N et al. Functional annotation of the human fat cell secretome. Arch Physiol Biochem 2012;118:84-91.
95. Trayhurn P, Drevon CA, Eckel J. Secreted proteins from adipose tissue and skeletal muscle - adipokines, myokines and adipose/muscle cross-talk. Arch Physiol Biochem 2011;117:47-56.
96. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
97. Dumond H, Presle N, Terlain B et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003;48:3118-29.
98. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived antiinflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-9.
99. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003;88:5452-5.
100. Yannakoulia M, Yiannakouris N, Bluher S et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003;88:1730-6.
101. Berndt J, Kloting N, Kralisch S et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-6.
102. Wang Y, Lam KS, Kraegen EW et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53:34-41.
103. Yan QW, Yang Q, Mody N et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56:2533-40.
104. Bozaoglu K, Bolton K, McMillan J et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-94.
105. Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. Endocrinology 2010;151:2590-602.
106. Griffin TM, Huebner JL, Kraus VB, Guilak F. Extreme obesity due to impaired leptin signaling in mice does not cause knee osteoarthritis. Arthritis Rheum 2009;60:2935-44.
107. Yang WH, Liu SC, Tsai CH et al. Leptin induces IL-6 expression through OBRl receptor signaling pathway in human synovial fibroblasts. PloS One 2013;8:e75551.
108. Tong KM, Shieh DC, Chen CP et al. Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K, Akt cascade and promotion of NF-kappaB/p300 binding in human synovial fibroblasts. Cell Signal 2008;20:1478-88.
109. Bao JP, Chen WP, Feng J et al. Leptin plays a catabolic role on articular cartilage. Mol Biol Rep 2010;37:3265-72.
110. Hui W, Litherland GJ, Elias MS et al. Leptin produced by joint white adipose tissue induces cartilage degradation via upregulation and activation of matrix metalloproteinases. Ann Rheum Dis 2012;71:455-62.
111. Honsawek S, Chayanupatkul M. Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Arch Med Res 2010;41:593-8.
112. Tang CH, Chiu YC, Tan TW, Yang RS, Fu WM. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J Immunol 2007;179:5483-92.
113. Ehling A, Schaffler A, Herfarth H et al. The potential of adiponectin in driving arthritis. J Immunol 2006;176:4468-78.
114. Zuo W, Wu ZH, Wu N et al. Adiponectin receptor 1 mediates the difference in adiponectin-induced prostaglandin E2 production in rheumatoid arthritis and osteoarthritis synovial fibroblasts. Chin Med J 2011;124:3919-24.
115. Lago R, Gomez R, Otero M et al. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthr Cartil 2008;16:1101-9.
116. Chen TH, Chen L, Hsieh MS et al. Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta 2006;1762:711-8.
117. Choe JY, Bae J, Jung HY et al. Serum resistin level is associated with radiographic changes in hand osteoarthritis: cross-sectional study. Joint Bone Spine 2012;79:160-5.
118. Filkova M, Liskova M, Hulejova H et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis 2009;68:295-6.
119. Yusuf E, Ioan-Facsinay A, Bijsterbosch J et al. Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis 2011;70:1282-4.
120. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789-95.
121. Lee JH, Ort T, Ma K et al. Resistin is elevated following traumatic joint injury and causes matrix degradation and release of inflammatory cytokines from articular cartilage in vitro. Osteoarthr Cartil 2009;17:613-20.
122. Zhang Z, Xing X, Hensley G et al. Resistin induces expression of proinflammatory cytokines and chemokines in human articular chondrocytes via transcription and messenger RNA stabilization. Arthritis Rheum 2010;62:1993-2003.
123. Duan Y, Hao D, Li M et al. Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis. Rheumatol Int 2012;32:985-90.
124. Laiguillon MC, Bougault C, Gosset M et al. Visfatin/NAMPT in osteoarthritis: a pro-inflammatory adipokine involved in synovium-cartilage and synovium-bone communications. Osteoarthr Cartil 2013;21(Suppl):S15-6.
125. Evans L, Williams AS, Hayes AJ, Jones SA, Nowell M. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colonyenhancing factor/visfatin/nicotinamide phosphoribosyltransferase:Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis Rheum 2011;63:1866-77.
126. Meier FM, Frommer KW, Peters MA et al. Visfatin/pre-Bcell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis. J Biol Chem 2012;287:28378-85.
127. Gosset M, Berenbaum F, Salvat C et al. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes:possible influence on osteoarthritis. Arthritis Rheum 2008;58:1399-409.
128. Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqqi TM. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum 2007;56:3326-35.
129. Huang K, Du G, Li L, Liang H, Zhang B. Association of chemerin levels in synovial fluid with the severity of knee osteoarthritis. Biomarkers 2012;17:16-20.
130. Eisinger K, Bauer S, Schaffler A et al. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. Exp Mol Pathol 2012;92:90-6.
131. Wittamer V, Franssen JD, Vulcano M et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-85.
132. Berg V, Sveinbjornsson B, Bendiksen S et al. Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157). Arthritis Res Ther 2010;12:R228.
133. Houseknecht KL, Baile CA, Matteri RL, Spurlock ME. The biology of leptin: a review. J Anim Sci 1998;76:1405-20.
134. Bas S, Finckh A, Puskas GJ et al. Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee. Int Orthop 2014. Advance Access published 9 July 2014, doi: 10.1007/s00264-014-2416-9.
135. Yaykasli KO, Hatipoglu OF, Yaykasli E et al. Leptin induces ADAMTS-4, ADAMTS-5, and ADAMTS-9 genes expression by mitogen-activated protein kinases and NF-kB signaling pathways in human chondrocytes. Cell Biol Int 2014. Advance Access published 15 July 2014, doi: 10.1002/cbin.10336.
136. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006;8:264-80.
137. Laurberg TB, Frystyk J, Ellingsen T et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol 2009;36:1885-91.
138. Gross JB, Guillaume C, Gégout-Pottie P, Mainard D, Presle N. Synovial fluid levels of adipokines in osteoarthritis:association with local factors of inflammation and cartilage maintenance. Biomed Mater Eng 2014;24:17-25.
139. Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46:459-69.
140. Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-9.
141. Ouchi N, Kihara S, Arita Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-63.
142. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975-81.
143. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-41.
144. Matsuura F, Oku H, Koseki M et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007;358:1091-5.
145. Oku H, Matsuura F, Koseki M et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 2007;581:5029-33.
146. Rene Gonzalez R, Watters A, Xu Y et al. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 2009;11:R36.